Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aardvark Therapeutics

13.40
-0.1200-0.89%
Volume:8.51K
Turnover:114.87K
Market Cap:286.55M
PE:-20.68
High:14.03
Open:13.57
Low:13.26
Close:13.52
Loading ...

Aardvark Therapeutics Inc : H.c. Wainwright Initiates Coverage With Buy Rating; Target Price $40.00

THOMSON REUTERS
·
30 Jun

HC Wainwright Initiates Aardvark Therapeutics at Buy With $40 Price Target

MT Newswires Live
·
30 Jun

Aardvark Therapeutics Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
30 Jun

Aardvark Therapeutics Announces Phase 3 HERO Study Enrollment for ARD-101 in Prader-Willi Syndrome at 2025 United in Hope Conference

Reuters
·
24 Jun

Aardvark Therapeutics appoints Timothy Kieffer as CSO, Danny Villeneuve as CCO

TIPRANKS
·
20 May

Aardvark Therapeutics Inc. Strengthens Leadership Team with Key Appointments in Scientific, Commercial, Regulatory, and Legal Roles

Reuters
·
20 May

Press Release: Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions

Dow Jones
·
20 May

Aardvark Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
15 May

Aardvark Therapeutics Inc trading resumes

TIPRANKS
·
15 May

Aardvark Therapeutics Inc trading halted, volatility trading pause

TIPRANKS
·
15 May

RBC Trims Price Target on Aardvark Therapeutics to $20 From $21, Keeps Outperform, Speculative Risk

MT Newswires Live
·
15 May

BRIEF-Aardvark Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights

Reuters
·
15 May

Aardvark Therapeutics Q1 EPS $(0.71) Down From $(0.55) YoY

Benzinga
·
15 May

Aardvark Therapeutics Reports Q1 2025 Results: Net Loss Widens to $9.3M; R&D Expenses Surge

Reuters
·
15 May

Aardvark Therapeutics Inc - as of March 31, 2025, Aardvark Had Cash, Cash Equivalents, and Short-Term Investments of $151.3 Mln

THOMSON REUTERS
·
15 May

Aardvark Therapeutics Price Target Maintained With a $50.00/Share by Cantor Fitzgerald

Dow Jones
·
01 Apr

Aardvark Therapeutics FY24 EPS (5.15) Down From ($1.82) YoY

Benzinga
·
01 Apr

Press Release: Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights

Dow Jones
·
01 Apr

BUZZ-Ultragenyx Pharma up after JPMorgan PT raise

Reuters
·
27 Mar

Aardvark Therapeutics Is Maintained at Buy by B of A Securities

Dow Jones
·
27 Mar